BRIEF—Positive Ph III data for Athenex and Almirall's KX2-391

US-based biotech Athenex and Spanish dermatology specialist Almirall have announced positive topline results from two Phase III studies of the experimental ointment KX2-391.

The firms are developing the therapy, a first-in-class dual Src kinase and tubulin polymerization inhibitor, as a treatment of actinic keratosis (AK).

Athenex chief medical officer Rudolf Kwan said the KX2-391 ointment “demonstrated excellent activity in the treatment of AK on the face or scalp,” and that it was “very well tolerated and over 99% of patients completed treatment.”

The firm plans to discuss the results with the US regulator.